News

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The Swiss-designed phaco platform provides mobility, simplified workflows, and reduced surgical waste for cataract procedures, according to the company.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Oluwatosin U. Smith, MD, highlights the practical impact of expanding tools on real-world glaucoma treatment.

Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.

Daniela Ferrara, MD, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.